• Markets
    • icon
  • Companies
ANR · ASX

Anatara Lifesciences Ltd (ASX:ANR)

AU$0.028

 0.0 (0.0%)
ASX:Live
27/11/2023 12:00:00 AM
HALO Ords GROWTH AUS All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

ANR Overview

ANR Health Scores

Short Term

Mean Revision

Trend

Event

Halo Model

MQV

GARP

MQV Small

Valuation

Value

Consensus

Momentum

Price

Earnings

Growth

Earnings

Dividends

Quality

Capital Efficiency

Balance Sheet

About ANR

Website

N/A

Telephone

N/A

Address

Description

Anatara Lifesciences Ltd. engages in the development of non-antibiotic oral solutions for gastrointestinal diseases in animals and humans. It also develops and commercializes Detach, a non-antibiotic therapy that prevents and treats diarrhea in piglets. The company was founded by Tracey Mynott on July 15, 2010 and is headquartered in Adelaide, Australia.

ANR Price Chart

Key Stats

Market Cap

AU$4.70M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.02 - 0.05

Trade Value (12mth)

AU$1,409.00

1 week

0%

1 month

-6.79%

YTD

-0.58%

1 year

-21.51%

All time high

1.66427

Key Fundamentals

EPS 3 yr Growth

-70.400%

EBITDA Margin

N/A

Operating Cashflow

-$2m

Free Cash Flow Return

-193.50%

ROIC

-173.40%

Interest Coverage

-1,375.60

Quick Ratio

2.90

Other Data

Shares on Issue (Fully Dilluted)

128m

HALO Sector

Healthcare

Next Company Report Date

28-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

ANR Announcements

Latest Announcements

Date Announcements

31 October 23

Appendix 4C & Q1 FY24 Activities Report

×

Appendix 4C & Q1 FY24 Activities Report

31 October 22

Entitlement Offer Letter to Shareholders

×

Entitlement Offer Letter to Shareholders

31 October 22

Change in substantial holding from TEK

×

Change in substantial holding from TEK

31 October 22

Change in substantial holding - Tiga Trading Pty Ltd

×

Change in substantial holding - Tiga Trading Pty Ltd

31 March 22

Clinical Trials Update

×

Clinical Trials Update

31 July 23

Appendix 4C & Q4 FY23 Activities Report

×

Appendix 4C & Q4 FY23 Activities Report

31 August 23

IBS clinical trial Stage 1 patients finalised

×

IBS clinical trial Stage 1 patients finalised

30 November 22

Change of Director's Interest Notice

×

Change of Director's Interest Notice

30 January 23

Application for quotation of securities - ANR

×

Application for quotation of securities - ANR

29 September 21

Annual General Meeting & Director Nominations

×

Annual General Meeting & Director Nominations

29 September 17

Annual Report 2017

×

Annual Report 2017

29 October 20

Investor Presentation

×

Investor Presentation

29 July 22

Quarterly Appendix 4C Cash Flow Report

×

Quarterly Appendix 4C Cash Flow Report

29 August 22

Appendix 4E & Audited Financial Report 30 June 2022

×

Appendix 4E & Audited Financial Report 30 June 2022

29 April 22

Appendix 4C and Q3 FY22 Activities Report

×

Appendix 4C and Q3 FY22 Activities Report

28 September 23

ANR announces Positive Results from Stage 1 of IBS trial

×

ANR announces Positive Results from Stage 1 of IBS trial

28 October 22

Appendix 4C & Q1 FY23 Activities Report

×

Appendix 4C & Q1 FY23 Activities Report

28 October 22

Application for quotation of securities - ANR

×

Application for quotation of securities - ANR

28 October 22

Cleansing Notice

×

Cleansing Notice

28 November 22

Application for quotation of securities - ANR

×

Application for quotation of securities - ANR

28 November 22

Notification regarding unquoted securities - ANR

×

Notification regarding unquoted securities - ANR

28 November 19

Anatara Investor Presentation and Update

×

Anatara Investor Presentation and Update

28 March 23

Change in substantial holding

×

Change in substantial holding

28 January 22

Appendix 4C and Q2 FY22 Activities Report

×

Appendix 4C and Q2 FY22 Activities Report

27 October 20

Annual Report to shareholders

×

Annual Report to shareholders

27 October 20

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

27 January 22

Appendix 4C and Q2 FY22 Activities Report

×

Appendix 4C and Q2 FY22 Activities Report

26 September 23

Pause in Trading

×

Pause in Trading

ANR Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.03 -0.03 -0.02 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.03 -0.03 -0.02 Lock Lock Lock
     Growth % Lock Lock Lock Lock 53.0 -12.0 43.8 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.03 -0.03 -0.02 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.03 -0.03 -0.02 Lock Lock Lock
     Growth % Lock Lock Lock Lock 56.3 -27.9 54.3 Lock Lock Lock
     Yield % Lock Lock Lock Lock -21.6 -57.2 -82.4 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.05 0.02 0.01 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.05 0.02 0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock -4.8 -64.9 -60.9 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 65 73 104 Lock Lock Lock
Basic m Lock Lock Lock Lock 65 73 104 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 3 3 3 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock 61.1 -293.9 -0.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -3 -3 -3 Lock Lock Lock
     Growth % Lock Lock Lock Lock 25.9 3.5 -8.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -3 -3 -3 Lock Lock Lock
     Growth % Lock Lock Lock Lock 26.0 2.9 -8.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -3 -3 -3 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -1 0 -1 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -2 -3 -2 Lock Lock Lock
     Growth % Lock Lock Lock Lock 40.7 -26.9 20.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -2 -2 -2 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 3 0 1 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -2 -2 -2 Lock Lock Lock
     Growth % Lock Lock Lock Lock 23.0 -6.6 -0.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 3 1 0 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 4 2 1 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -3 -1 0 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Equity $m Lock Lock Lock Lock 4 1 1 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 4 1 1 Lock Lock Lock
     Growth % Lock Lock Lock Lock 36.4 -63.8 -34.4 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -46.1 -143.3 -142.5 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -52.1 -185.6 -218.8 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -92.0 -113.2 -279.0 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -59.1 -95.5 -173.4 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -62.1 -84.2 -193.5 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock -10,354.9 -902.9 -1,375.6 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 1.1 0.4 0.1 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -87.5 -80.9 -43.4 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 10.5 4.7 2.9 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 10.5 4.7 2.9 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 80.9 68.8 28.3 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -521.0 -623.5 -456.9 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -46.1 -143.3 -142.5 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 1.3 1.5 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -52.1 -185.6 -218.8 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -52.1 -185.6 -218.8 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 6,685.0 2,575.9 1,705.6 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -6,685.0 -2,575.9 -1,705.6 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

ANR Shortsell

Frequently Asked Questions

The current share price of Anatara Lifesciences Ltd (ANR:ASX) is AU$0.028.
The 52-week high share price for Anatara Lifesciences Ltd (ANR:ASX) is AU$0.05.
The 52-week low share price for Anatara Lifesciences Ltd (ANR:ASX)? is AU$0.02.
Anatara Lifesciences Ltd (ANR:ASX) does not pay a dividend.
Anatara Lifesciences Ltd (ANR:ASX) does not pay a dividend.
Anatara Lifesciences Ltd (ANR:ASX) has a franking level of 0%.
Anatara Lifesciences Ltd (ANR:ASX) is classified in the Healthcare.
The current P/E ratio for Anatara Lifesciences Ltd (ANR:ASX) is .
halo-logo-inverted-rgb@72ppi-1
Login
Products
Company
Important

Get the latest insights and hot tips delivered right to your inbox

Apple Store
Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.